Medicenna Therapeutics Corp. (TSE:MDNA - Get Free Report) was up 4.6% during mid-day trading on Friday . The stock traded as high as C$0.92 and last traded at C$0.91. Approximately 4,855 shares changed hands during trading, a decline of 91% from the average daily volume of 51,231 shares. The stock had previously closed at C$0.87.
Medicenna Therapeutics Price Performance
The business's fifty day simple moving average is C$1.02 and its 200 day simple moving average is C$1.25. The firm has a market capitalization of C$68.08 million, a price-to-earnings ratio of -2.51 and a beta of 1.21. The company has a debt-to-equity ratio of 0.88, a current ratio of 11.40 and a quick ratio of 4.65.
Medicenna Therapeutics Company Profile
(
Get Free Report)
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medicenna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medicenna Therapeutics wasn't on the list.
While Medicenna Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
